…
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Quest Diagnostics operates one of the largest clinical laboratory networks in the U.S., providing diagnostic testing, information services and health insights to hospitals, clinicians, employers and patients. Long-term growth may be supported by demographic-driven demand for routine and advanced diagnostics, expansion into genomic and data-enabled services, and scale advantages from its national footprint, which could make the company attractive to investors seeking exposure to recurring healthcare-driven revenue.
Principal risks include sustained reimbursement pressure and pricing competition, regulatory and compliance demands for laboratory operations, and potential disruption from point-of-care and decentralized testing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 1360.00M | 1194.00M | 1130.00M | 1235.00M | 2599.00M |
| Minority interest | -54.00M | -50.00M | -56.00M | -69.00M | -85.00M |
| Net income | 992.00M | 871.00M | 854.00M | 946.00M | 1995.00M |
| Selling general administrative | 1920.00M | 1770.00M | 1798.00M | 1818.00M | 1727.00M |
| Gross profit | 3523.00M | 3244.00M | 3053.00M | 3433.00M | 4209.00M |
| Reconciled depreciation | 570.00M | 493.00M | 446.00M | 437.00M | 408.00M |
| Ebit | 1624.00M | 1401.00M | 1262.00M | 1428.00M | 2381.00M |
| Ebitda | 2194.00M | 1894.00M | 1262.00M | 1810.00M | 3158.00M |
| Depreciation and amortization | 570.00M | 493.00M | 439.00M | 382.00M | 777.00M |
| Non operating income net other | - | - | - | -11.00M | 447.00M |
| Operating income | 1603.00M | 1346.00M | 1262.00M | 1428.00M | 2381.00M |
| Other operating expenses | 9432.00M | 8526.00M | 7990.00M | 8455.00M | 8407.00M |
| Interest expense | 264.00M | 226.00M | 152.00M | 138.00M | 151.00M |
| Tax provision | 314.00M | 273.00M | 204.00M | 264.00M | 597.00M |
| Interest income | 264.00M | 25.00M | 9.00M | 138.00M | 151.00M |
| Net interest income | -264.00M | -201.00M | -144.00M | -138.00M | -151.00M |
| Income tax expense | 314.00M | 273.00M | -248.00M | 264.00M | 597.00M |
| Total revenue | 11035.00M | 9872.00M | 9252.00M | 9883.00M | 10788.00M |
| Total operating expenses | 1920.00M | 1898.00M | 1642.00M | 2005.00M | 1828.00M |
| Cost of revenue | 7512.00M | 6628.00M | 6199.00M | 6450.00M | 6579.00M |
| Total other income expense net | -243.00M | -152.00M | -132.00M | -193.00M | 218.00M |
| Net income from continuing ops | 1046.00M | 921.00M | 819.00M | 1015.00M | 2080.00M |
| Net income applicable to common shares | 988.00M | 866.00M | 850.00M | 942.00M | 1988.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 16225.00M | 16153.00M | 14022.00M | 12837.00M | 13611.00M |
| Intangible assets | 1636.00M | 1763.00M | 1166.00M | 1092.00M | 1167.00M |
| Other current assets | 361.00M | 351.00M | 286.00M | 196.00M | 223.00M |
| Total liab | 8939.00M | 9257.00M | 7604.00M | 6830.00M | 7049.00M |
| Total stockholder equity | 7170.00M | 6778.00M | 6307.00M | 5893.00M | 6444.00M |
| Other current liab | - | 945.00M | 852.00M | 1072.00M | 1243.00M |
| Common stock | 2.00M | 2.00M | 2.00M | 2.00M | 2.00M |
| Capital stock | 2.00M | 2.00M | 2.00M | 2.00M | 2.00M |
| Retained earnings | 9994.00M | 9360.00M | 8825.00M | 8290.00M | 7649.00M |
| Other liab | - | - | - | 812.00M | 792.00M |
| Good will | 8945.00M | 8856.00M | 7733.00M | 7220.00M | 7095.00M |
| Other assets | 270.00M | 255.00M | 198.00M | 144.00M | 163.00M |
| Cash | 420.00M | 549.00M | 686.00M | 315.00M | 872.00M |
| Cash and equivalents | 420.00M | 549.00M | 686.00M | 315.00M | 872.00M |
| Total current liabilities | 2278.00M | 2169.00M | 1815.00M | 1551.00M | 1753.00M |
| Current deferred revenue | - | - | 516.00M | - | - |
| Net debt | 6499.00M | 6538.00M | 4812.00M | 4307.00M | 3785.00M |
| Short term debt | 678.00M | 937.00M | 585.00M | 155.00M | 153.00M |
| Short long term debt | 707.00M | 764.00M | 432.00M | 2.00M | 2.00M |
| Short long term debt total | 6919.00M | 7087.00M | 5498.00M | 4622.00M | 4657.00M |
| Other stockholder equity | -2799.00M | -2496.00M | -2506.00M | -2378.00M | -1193.00M |
| Property plant equipment | 2860.00M | 2764.00M | 2418.00M | 2351.00M | 2304.00M |
| Total current assets | 2378.00M | 2392.00M | 2372.00M | 1898.00M | 2741.00M |
| Long term investments | 136.00M | 123.00M | 135.00M | 132.00M | 141.00M |
| Net tangible assets | - | - | - | -1853.00M | -1818.00M |
| Net receivables | 1408.00M | 1304.00M | 1210.00M | 1195.00M | 1438.00M |
| Long term debt | 5167.00M | 5615.00M | 4410.00M | 3978.00M | 4010.00M |
| Inventory | 189.00M | 188.00M | 190.00M | 192.00M | 208.00M |
| Accounts payable | 1600.00M | 287.00M | 378.00M | 324.00M | 357.00M |
| Noncontrolling interest in consolidated entity | - | - | - | 37.00M | 39.00M |
| Accumulated other comprehensive income | -27.00M | -88.00M | -14.00M | -21.00M | -14.00M |
| Common stock total equity | - | - | - | 2.00M | 2.00M |
| Retained earnings total equity | - | - | - | 8290.00M | 7649.00M |
| Treasury stock | - | - | - | -4673.00M | -3453.00M |
| Non currrent assets other | 270.00M | 255.00M | 198.00M | 144.00M | 163.00M |
| Non current assets total | 13847.00M | 13761.00M | 11650.00M | 10939.00M | 10870.00M |
| Capital lease obligations | 711.00M | 708.00M | 656.00M | 642.00M | 645.00M |
| Long term debt total | 5167.00M | 5615.00M | 4410.00M | 3978.00M | 4010.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -2548.00M | -1121.00M | -543.00M | 752.00M |
| Change to liabilities | - | - | - | -180.00M | 35.00M |
| Total cashflows from investing activities | -631.00M | -2548.00M | -1061.00M | -543.00M | 21.00M |
| Net borrowings | -602.00M | 1543.00M | 748.00M | -2.00M | -2.00M |
| Total cash from financing activities | -1388.00M | 1084.00M | 160.00M | -1732.00M | -2540.00M |
| Change to operating activities | - | - | - | 53.00M | -9.00M |
| Net income | 1046.00M | 921.00M | 908.00M | 1015.00M | 2080.00M |
| Change in cash | -129.00M | -137.00M | 371.00M | -557.00M | -286.00M |
| Begin period cash flow | 549.00M | 686.00M | 315.00M | 872.00M | 1158.00M |
| End period cash flow | 420.00M | 549.00M | 686.00M | 315.00M | 872.00M |
| Total cash from operating activities | 1886.00M | 1334.00M | 1272.00M | 1718.00M | 2233.00M |
| Depreciation | 570.00M | 493.00M | 439.00M | 437.00M | 408.00M |
| Other cashflows from investing activities | -3.00M | 41.00M | -42.00M | -139.00M | 424.00M |
| Dividends paid | 353.00M | 331.00M | 314.00M | -305.00M | -309.00M |
| Change to inventory | - | - | - | - | -20.00M |
| Change to account receivables | -106.00M | -71.00M | -15.00M | 246.00M | 81.00M |
| Sale purchase of stock | -450.00M | -151.00M | -275.00M | -1408.00M | -2199.00M |
| Other cashflows from financing activities | -62.00M | 23.00M | 1.00M | -17.00M | -159.00M |
| Change to netincome | - | - | - | 147.00M | -257.00M |
| Capital expenditures | 527.00M | 425.00M | 408.00M | 404.00M | 403.00M |
| Change receivables | - | - | - | 246.00M | 81.00M |
| Cash flows other operating | - | - | - | 53.00M | -323.00M |
| Cash and cash equivalents changes | - | - | - | -557.00M | -286.00M |
| Change in working capital | 50.00M | -201.00M | -145.00M | 119.00M | 87.00M |
| Stock based compensation | 88.00M | 88.00M | 77.00M | 77.00M | 79.00M |
| Other non cash items | 27.00M | 20.00M | 42.00M | 69.00M | -364.00M |
| Free cash flow | 1359.00M | 909.00M | 864.00M | 1314.00M | 1830.00M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics Incorporated |
3.70 1.45% |
259.33 | 22.43 | 18.48 | 2.06 | 3.03 | 2.53 | 12.88 |
| TMO Thermo Fisher Scientific Inc |
26.87 3.87% |
721.63 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
4.87 2.12% |
235.12 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
-0.93 3.65% |
24.52 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
2.07 8.27% |
27.08 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
500 Plaza Drive, Secaucus, NJ, United States, 07094
973 520 2700
46000
| Name | Title | Year Born |
|---|---|---|
| Mr. Stephen H. Rusckowski | Exec. Chairman | 1957 |
| Mr. James E. Davis | CEO, Pres & Director | 1963 |
| Ms. Catherine T. Doherty | Sr. VP of Regional Bus.es | 1963 |
| Mr. Sam A. Samad | Exec. VP & CFO | 1970 |
| Mr. Michael J. Deppe | VP, Corp. Controller & Chief Accounting Officer | 1967 |
| Ms. Gabrielle Wolfson | Sr. VP and Chief Information & Digital Officer | NA |
| Mr. Shawn C. Bevec | VP of Investor Relations | NA |
| Mr. Michael E. Prevoznik | Sr. VP & Gen. Counsel | 1962 |
| Ms. Kristin Lee Wallace Esq. | Sr. VP of Compliance | NA |
| Mr. Gary D. Samuels | Sr. VP & Chief Communications Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.